Amicus Therapeutics, Inc. (NASDAQ:FOLD) SVP Daphne Quimi sold 7,000 shares of the firm’s stock in a transaction on Thursday, October 12th. The shares were sold at an average price of $14.25, for a total value of $99,750.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Amicus Therapeutics, Inc. (NASDAQ FOLD) traded up 4.31% during mid-day trading on Friday, hitting $14.03. The company had a trading volume of 2,576,397 shares. The firm’s market capitalization is $2.31 billion. Amicus Therapeutics, Inc. has a 12-month low of $4.41 and a 12-month high of $16.60. The company’s 50 day moving average price is $14.35 and its 200-day moving average price is $11.26.
Amicus Therapeutics (NASDAQ:FOLD) last posted its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.03. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 61.25%. The firm had revenue of $7.16 million for the quarter, compared to analysts’ expectations of $6.96 million. During the same quarter last year, the firm earned ($0.40) EPS. On average, analysts forecast that Amicus Therapeutics, Inc. will post ($1.32) EPS for the current fiscal year.
WARNING: “Amicus Therapeutics, Inc. (NASDAQ:FOLD) SVP Daphne Quimi Sells 7,000 Shares” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.dispatchtribunal.com/2017/10/28/insider-selling-amicus-therapeutics-inc-fold-svp-sells-99750-00-in-stock.html.
Hedge funds have recently modified their holdings of the company. Strs Ohio purchased a new stake in shares of Amicus Therapeutics during the 3rd quarter worth approximately $102,000. Teacher Retirement System of Texas increased its stake in shares of Amicus Therapeutics by 1.7% during the 2nd quarter. Teacher Retirement System of Texas now owns 10,243 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 169 shares during the last quarter. DORCHESTER WEALTH MANAGEMENT Co purchased a new position in Amicus Therapeutics in the 2nd quarter valued at approximately $111,000. Tudor Investment Corp ET AL purchased a new position in Amicus Therapeutics in the 2nd quarter valued at approximately $124,000. Finally, Aperio Group LLC grew its stake in Amicus Therapeutics by 13.5% in the 2nd quarter. Aperio Group LLC now owns 13,986 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 1,663 shares in the last quarter.
Several equities research analysts have recently commented on the company. Leerink Swann reissued a “buy” rating and issued a $20.00 target price (up from $17.00) on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. Robert W. Baird restated an “outperform” rating and issued a $16.00 price target on shares of Amicus Therapeutics in a research report on Monday, September 25th. J P Morgan Chase & Co restated an “overweight” rating and issued a $15.00 price target (up from $13.00) on shares of Amicus Therapeutics in a research report on Wednesday, August 9th. Cowen and Company restated a “buy” rating and issued a $16.00 price target on shares of Amicus Therapeutics in a research report on Monday, August 14th. Finally, Zacks Investment Research lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 12th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $17.81.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.